The FDA has posted an ongoing Class II recall of clobetasol propionate cream USP 0.05% in 60 g tubes, manufactured for Lupin Pharmaceuticals, for failing content uniformity specifications.
Content uniformity is the test that the active drug is evenly distributed through the batch - so a failure means the amount of clobetasol in a given tube, or in a given part of a tube, is not reliably what the label says. Class II means the defect may cause temporary or medically reversible harm, with serious harm unlikely. For a superpotent topical steroid the failure cuts both ways: an under-dosed tube looks like treatment failure and invites escalation, while an over-dosed one raises the risk of atrophy, striae and adrenal suppression, particularly in children and on thin skin.
What to do is practical, not dramatic. If a patient's clobetasol has stopped working, or a steroid reaction appears out of proportion to what was prescribed, check the tube and the batch before changing the treatment plan. In India, the affected product is a US-market batch and CDSCO has issued no corresponding action that we can confirm - so this is a prompt to check provenance, not a reason to tell patients to stop a working treatment.
- Check tube and batch details if clobetasol has unexpectedly stopped working
- Consider a batch problem before escalating potency or adding a systemic agent
- Watch for atrophy or striae disproportionate to the prescribed quantity
- Do not tell patients on a working tube to stop - a Class II recall is not an urgent safety alert
- Record the brand and batch in the notes for patients on long-term superpotent steroids
Why it matters
A manufacturing failure in a superpotent steroid presents in clinic as treatment failure or as an unexplained steroid side effect - not as a recall notice.
Don't overread it
This is a manufacturing specification failure in specified batches, not a safety finding about clobetasol as a drug.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free